{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,5]],"date-time":"2024-07-05T02:21:47Z","timestamp":1720146107047},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,12,1]],"date-time":"2017-12-01T00:00:00Z","timestamp":1512086400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Japan Tobacco Inc."}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Life Sciences"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1016\/j.lfs.2017.10.029","type":"journal-article","created":{"date-parts":[[2017,10,19]],"date-time":"2017-10-19T17:31:28Z","timestamp":1508434288000},"page":"166-174","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["JTE-852, a novel spleen tyrosine kinase inhibitor, blocks immunoglobulin G-mediated cellular responses and autoimmune reactions in vivo"],"prefix":"10.1016","volume":"191","author":[{"given":"Toshinobu","family":"Kato","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeshi","family":"Ohta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hidenori","family":"Iwasaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hatsue","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akira","family":"Matsuo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahiro","family":"Hata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mutsuyoshi","family":"Matsushita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"Suppl. 7","key":"10.1016\/j.lfs.2017.10.029_bb0005","first-page":"S136","article-title":"Current therapeutic agents and treatment paradigms for the management of rheumatoid arthritis","volume":"20","author":"Gibofsky","year":"2014","journal-title":"Am. J. Manag. Care"},{"issue":"Suppl. 3","key":"10.1016\/j.lfs.2017.10.029_bb0010","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1365-2133.2012.11208.x","article-title":"Long-term safety of biologics in the treatment of moderate-to-severe plaque psoriasis: review of current data","volume":"167","author":"Rustin","year":"2012","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.lfs.2017.10.029_bb0015","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.intimp.2015.04.049","article-title":"Upcoming biological therapies in systemic lupus erythematosus","volume":"27","author":"Sciascia","year":"2015","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.lfs.2017.10.029_bb0020","doi-asserted-by":"crossref","first-page":"121","DOI":"10.2174\/1871528113666140224103712","article-title":"The risk of progressive multifocal leukoencephalopathy under biological agents used in the treatment of chronic inflammatory diseases","volume":"13","author":"Toussirot","year":"2014","journal-title":"Inflamm. Allergy Drug Targets"},{"key":"10.1016\/j.lfs.2017.10.029_bb0025","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.clim.2007.06.005","article-title":"Syk kinase as a treatment target for therapy in autoimmune diseases","volume":"124","author":"Kyttaris","year":"2007","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.lfs.2017.10.029_bb0030","doi-asserted-by":"crossref","first-page":"245","DOI":"10.2147\/DDDT.S25426","article-title":"Kinase inhibitors: a new class of antirheumatic drugs","volume":"6","author":"Kyttaris","year":"2012","journal-title":"Drug Des. Devel. Ther."},{"key":"10.1016\/j.lfs.2017.10.029_bb0035","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1517\/13543784.13.7.743","article-title":"Targeting Syk as a treatment for allergic and autoimmune disorders","volume":"13","author":"Wong","year":"2004","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.lfs.2017.10.029_bb0040","doi-asserted-by":"crossref","first-page":"123","DOI":"10.2174\/1389557515666150101101850","article-title":"Small molecular inhibitors for the treatment of rheumatoid arthritis: progress so far","volume":"15","author":"Kurdekar","year":"2015","journal-title":"Mini-Rev. Med. Chem."},{"key":"10.1016\/j.lfs.2017.10.029_bb0045","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejphar.2017.02.048","article-title":"JTE-852, a novel spleen tyrosine kinase inhibitor, blocks mediator secretion from mast cells with immunoglobulin E crosslinking","volume":"801","author":"Kato","year":"2017","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.lfs.2017.10.029_bb0050","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.tips.2014.05.007","article-title":"Getting Syk: spleen tyrosine kinase as a therapeutic target","volume":"35","author":"Geahlen","year":"2014","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.lfs.2017.10.029_bb0055","doi-asserted-by":"crossref","first-page":"78","DOI":"10.3389\/fimmu.2016.00078","article-title":"Targeting Syk in autoimmune rheumatic diseases","volume":"7","author":"Deng","year":"2016","journal-title":"Front. Immunol."},{"key":"10.1016\/j.lfs.2017.10.029_bb0060","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1586\/1744666X.2014.962996","article-title":"Methotrexate: an old new drug in autoimmune disease","volume":"10","author":"Cipriani","year":"2014","journal-title":"Expert. Rev. Clin. Immunol."},{"key":"10.1016\/j.lfs.2017.10.029_bb0065","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.2174\/13894501113149990604","article-title":"Methotrexate: should we start using it in clinical practice?","volume":"14","author":"Miheller","year":"2013","journal-title":"Curr. Drug Targets"},{"key":"10.1016\/j.lfs.2017.10.029_bb0070","first-page":"267","article-title":"Effects of DS-4574, a new orally active antiallergic agent, in experimental allergic and inflammatory models","volume":"61","author":"Aibara","year":"1993","journal-title":"Jpn. J. Pharmacol."},{"key":"10.1016\/j.lfs.2017.10.029_bb0075","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1248\/bpb.32.1057","article-title":"Effects of KP-496, a novel dual antagonist for cysteinyl leukotriene receptor 1 and thromboxane A2 receptor, on Sephadex-induced airway inflammation in rats","volume":"32","author":"Ishimura","year":"2009","journal-title":"Biol. Pharm. Bull."},{"key":"10.1016\/j.lfs.2017.10.029_bb0080","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/BF01997493","article-title":"Suppression of the Arthus reaction by Y-24180, a potent and specific antagonist of platelet-activating factor","volume":"35","author":"Okamoto","year":"1992","journal-title":"Agents Actions"},{"key":"10.1016\/j.lfs.2017.10.029_bb0085","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1084\/jem.158.6.2007","article-title":"Paradoxical effects of cyclosporin A on collagen arthritis in rats","volume":"158","author":"Kaibara","year":"1983","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.lfs.2017.10.029_bb0090","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1124\/jpet.106.109058","article-title":"R406, an orally available spleen tyrosine kinase inhibitor blocks fc receptor signaling and reduces immune complex-mediated inflammation","volume":"319","author":"Braselmann","year":"2006","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.lfs.2017.10.029_bb0095","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0022-1759(02)00188-6","article-title":"Establishment of the superoxide production assay with human monocytic cell line, U937, for the evaluation of Syk kinase inhibitors","volume":"268","author":"Yamamoto","year":"2002","journal-title":"J. Immunol. Methods"},{"key":"10.1016\/j.lfs.2017.10.029_bb0100","series-title":"Cellular and Molecular Immunology","first-page":"404","article-title":"Diseases caused by immune responses: hypersensitivity and autoimmunity","author":"Abbas","year":"2000"},{"key":"10.1016\/j.lfs.2017.10.029_bb0105","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1038\/sj.jid.5700717","article-title":"Targeting effector memory T cells with the small molecule Kv1.3 blocker PAP-1 suppresses allergic contact dermatitis","volume":"127","author":"Azam","year":"2007","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.lfs.2017.10.029_bb0110","first-page":"131","article-title":"The role of CD4+ and CD8+ T cells in contact hypersensitivity and allergic contact dermatitis","volume":"14","author":"Saint-Mezard","year":"2004","journal-title":"Eur. J. Dermatol."},{"key":"10.1016\/j.lfs.2017.10.029_bb0115","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1016\/j.jaci.2006.05.023","article-title":"Identification of the Syk kinase inhibitor R112 by a human mast cell screen","volume":"118","author":"Rossi","year":"2006","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.lfs.2017.10.029_bb0120","series-title":"Cellular and Molecular Immunology","first-page":"161","article-title":"Activation of T lymphocytes","author":"Abbas","year":"2000"},{"issue":"Suppl. 2","key":"10.1016\/j.lfs.2017.10.029_bb0125","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1093\/rheumatology\/XXXIV.suppl_2.43","article-title":"Efficacy of methotrexate in rheumatoid arthritis","volume":"34","author":"Weinblatt","year":"1995","journal-title":"Br. J. Rheumatol."},{"key":"10.1016\/j.lfs.2017.10.029_bb0130","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1136\/ard.2004.026120","article-title":"Methotrexate ameliorates T cell dependent autoimmune arthritis and encephalomyelitis but not antibody induced or fibroblast induced arthritis","volume":"64","author":"Lange","year":"2005","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.lfs.2017.10.029_bb0135","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1111\/j.1365-2249.2007.03335.x","article-title":"Methotrexate induces poly(ADP-ribose) polymerase-dependent, caspase 3-independent apoptosis in subsets of proliferating CD4+ T cells","volume":"148","author":"Nielsen","year":"2007","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.lfs.2017.10.029_bb0140","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.intimp.2004.10.012","article-title":"FK506 ameliorates spontaneous locomotor activity in collagen-induced arthritis: implication of distinct effect from suppression of inflammation","volume":"5","author":"Sasakawa","year":"2005","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.lfs.2017.10.029_bb0145","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1093\/rheumatology\/ket225","article-title":"Inhibition of spleen tyrosine kinase in the treatment of rheumatoid arthritis","volume":"52","author":"Nijjar","year":"2013","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.lfs.2017.10.029_bb0150","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1056\/NEJMoa1000500","article-title":"An oral spleen tyrosine kinase (Syk) inhibitor for rheumatoid arthritis","volume":"363","author":"Weinblatt","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lfs.2017.10.029_bb0155","doi-asserted-by":"crossref","first-page":"3309","DOI":"10.1002\/art.23992","article-title":"Treatment of rheumatoid arthritis with a Syk kinase inhibitor: a twelve-week, randomized, placebo-controlled trial","volume":"58","author":"Weinblatt","year":"2008","journal-title":"Arthritis Rheum."}],"container-title":["Life Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002432051730543X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002432051730543X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,4,5]],"date-time":"2021-04-05T07:16:46Z","timestamp":1617607006000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S002432051730543X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12]]},"references-count":31,"alternative-id":["S002432051730543X"],"URL":"https:\/\/doi.org\/10.1016\/j.lfs.2017.10.029","relation":{},"ISSN":["0024-3205"],"issn-type":[{"value":"0024-3205","type":"print"}],"subject":[],"published":{"date-parts":[[2017,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"JTE-852, a novel spleen tyrosine kinase inhibitor, blocks immunoglobulin G-mediated cellular responses and autoimmune reactions in vivo","name":"articletitle","label":"Article Title"},{"value":"Life Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lfs.2017.10.029","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}